Filing Flows › Myriad Genetics (MYGN) › Cancer Care Continuum revenue
Myriad Genetics (MYGN) Cancer Care Continuum revenue by quarter
Myriad Genetics' Cancer Care Continuum revenue was $124M in Q3 2026 (third quarter 2026), +9% from Q2 2026. Over the last 3 quarters it ranged from $114M (Q2 2026) to $124M (Q3 2026).
| Quarter | Cancer Care Continuum revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $124M | +9% | — |
| Q2 2026 | $114M | -5% | — |
| Q1 2026 | $120M | — | — |
Q3 2026 at a glance
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Myriad Genetics' Cancer Care Continuum revenue?
Myriad Genetics' Cancer Care Continuum revenue was $124M in Q3 2026 (third quarter 2026), +9% from Q2 2026.
How has Myriad Genetics' Cancer Care Continuum revenue changed?
Over the last 3 quarters it ranged from $114M (Q2 2026) to $124M (Q3 2026).